Triomics
PrivateLast Round
Series B
May 27, 2026
Est. Valuation
$1.79M
Total Funding Raised
$51.39M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
Triomics is a healthcare technology company that provides an AI-powered platform to automate oncology workflows, including clinical trial matching, patient chart preparation, and data abstraction.
Sector
Healthcare & Life Sciences
Verticals
Medical AI, Clinical Trials, Healthcare Analytics
Business Model
B2B
Customer Profile
Subscription SaaS, Services & Consulting
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Triomics Comparables
Compare Triomics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Layer Health | 81% | |
| Oncora Medical | 80% | |
| Azra AI | 79% |
Triomics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | May 27, 2026 | ||||
| Series A | May 9, 2024 | ||||
| Series A | Feb 22, 2023 | ||||
| Accelerator | Mar 1, 2021 | ||||
| Seed | Jan 1, 2021 |
Triomics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| General Catalyst | Series A |
| Battery Ventures | Series B |
| Y Combinator | Seed, Series A, Accelerator, Series B |
| Oncology Ventures | Series B |
| Nexus Venture Partners | Series A, Series B |
| Lightspeed Venture Partners | Series A, Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 19, 2026
Grew 21% QoQ, from 72 to 87 employees.
- Jul 28, 2026
Grew 27% QoQ, from 64 to 81 employees.
Triomics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Triomics's valuation, stock price, and market status.
Is Triomics a public or private company?
Triomics is a private company.
What is the current stock price of Triomics?
Triomics is a private company, so its shares have no public market price. Caplight tracks Triomics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Triomics worth (valuation)?
Triomics's valuation is estimated at $1.8M based on funding round data.
Can I buy Triomics stock?
Triomics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Triomics's last funding round?
Triomics's most recent funding round was Series B on May 27, 2026.
Who are the main investors in Triomics?
Key investors in Triomics include Battery Ventures.
Will Triomics IPO soon?
No public IPO plans have been announced for Triomics.
How can I track Triomics secondary market activity?
Caplight tracks bids, offers, and trades in Triomics's shares on secondary markets.